In oncology, we increasingly notice an introduction of novel oral treatments. While this is certainly more convenient for patients and the benefits of this are great, patients’ non-adherence is now becoming a new challenge in oncology. Over recent years, Ingress-Health has gained extensive knowledge in this particular topic. Please find below our recording of the
Please join our colleagues at Cytel for this webinar series and join experts as they embark on two pilot projects on head-to-head comparisons using real world data. These projects in oncology and cardiovascular will occur in real time across the series. You will see the data and analytical challenges faced during the projects, and how these challenges
At Ingress-health, we’re committed to supporting a diverse workplace. This month and every month, we stand for equality and advocate for our #LGBTQ+ colleagues, friends and family. Join us in celebrating #PrideMonth by creating an inclusive environment for all. #LoveisLove #Equality #Diversity #Inclusion
Please join our Webinare the 23rd of June 2020, free of charge! If you would like to participate, please send confirmation to dyon.mertens@ingress-health.com.
In our recent publication, the Ingress-Health RWE team, together with clinical experts, analyzed a big German claims dataset with >8 million insured to explore unmet needs in patients with Inflammatory Bowel disease not treated with biologics. The team identified a substantial percentage of patients who suffer from active disease and/or steroid dependency, and the majority
According to the World Health Organization (WHO), 235 million people suffer from asthma worldwide. To learn more about potential barriers to therapy adherence in asthma, click here
Ingress-health B.V. and Indivumed GmbH announced today the launch of an exclusive partnership on real-world evidence (RWE) studies in oncology. Click here to find out more!
Lung cancer is the leading cause of cancer-associated mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for a majority of the reported cases. Ingress-health recently conducted a German claims data analysis to assess the real-world treatment of patients with NSCLC. Click here to find out more!
World Cancer Day empowers everyone around the world to show support, raise our collective voice and take action. We, at Ingress-Health, believe that there is a significant need to collect and analyze RWE to demonstrate drug effectiveness in clinical practice. Therefore, we developed a framework to use RWE along with clinical trial efficacy data to
Ingress-health is constantly eager to explore methods and frameworks for conducting patient preference research. In a recent study, the impact of the design of a discrete choice experiment on its results was analyzed. To find out more about this, check out our ISPOR poster. Click here to find out more.
